{"name":"Elion Therapeutics, Inc.","slug":"elion-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Elion Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for infectious diseases. The company currently has two drugs in Phase 2 clinical trials, demonstrating its commitment to advancing therapies that address significant unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Antifungal Comparator","genericName":"Antifungal Comparator","slug":"antifungal-comparator","indication":"Fungal infections","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EL219","genericName":"EL219","slug":"el219","indication":"Solid tumors (Phase 2 development)","status":"phase_2"}]}],"pipeline":[{"name":"Antifungal Comparator","genericName":"Antifungal Comparator","slug":"antifungal-comparator","phase":"phase_2","mechanism":"Antifungal mechanism involves inhibiting fungal cell wall synthesis","indications":["Fungal infections"],"catalyst":""},{"name":"EL219","genericName":"EL219","slug":"el219","phase":"phase_2","mechanism":"EL219 is an immunostimulatory agent designed to activate innate immune responses against cancer.","indications":["Solid tumors (Phase 2 development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQVWQxTDdWUnBzTFRkS0t4WDhMd08yQnpMekljN3ZqTnl3QjJwRU9nd05JY0lpRzZNMlNSa3Z3OGVLeFd2OVZIOFFaSm1sWUdWYXdaVTl4QVpDMG1lTFp5ajVuclFuU3JzNjdwUlNaeFFxSm9GSTVmcTdYaWZQS251akZEeGVUNmV6QVdvWm9JSThrdm5Id1JlblRRMUxPZTdDWVVuSXJId1p1a3ZhNlpwU0xCbEtIa2FhVHY4VDN0VEIwaUhab2otOUJ6RldaajNFTHZLZEtqTVNjNTRobDVkdm1DNklLbmhYbUZ0SDIyT1FtaTFyYlgwRUtXeVR0ZjhDLUptMEZpVV9DWE4ySFhtVWlDMDA4TF9LbHpvVmhjbWw3TkVl?oc=5","date":"2026-02-09","type":"pipeline","source":"PR Newswire UK","summary":"Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxOV21VUXZwczFkUFVrMk5yalVmV091YjdNaVlkNURLVzBjSEhGWmtHZzNOdTBCQVEtaXdEZVpHMzF0bUljaTBjdkh0dm02X0FPM0tzdEdpSFJyemlUaUlFWHFVMUxvQXVOaFROd0E5UlZKYXpTSk5OMDF2dnZmQWs0SzhYSzNtd190SUhZTHE1MGZRYnlDbkdiTzZHbGhhRlNqYW9qeVFySWhHX2tSX3pteE1TcXJ0Zk1jaXZXUnJLaXpNMlFiV21nanlGWmFySmQ4bHNQQ2tKR0t1MGRwQnNzakRDaWRKazRjelplbUpKV0pSdTQ3SFhLeQ?oc=5","date":"2025-12-02","type":"pipeline","source":"Business Wire","summary":"IDWeek: Annual Meeting 2025 Highlights - Covering HIV, COVID-19, RSV, NTM, UTIs, and More - ResearchAndMarkets.com - Business Wire","headline":"IDWeek: Annual Meeting 2025 Highlights - Covering HIV, COVID-19, RSV, NTM, UTIs, and More - ResearchAndMarkets.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQU1ljbUVoX052VWtuSWpUaGc5XzBrLTAxUXJERC15blpjbEVsZDVwWGxTdWxVS05WRzRtal92WVNoWXozNUsxOFpJV0FocUQ0Y00wTmhhWXFlUWtzaVd3MGJ1SWtnZTFMVEdJdDdtTU1Rakk2d2Q3MkhwaHozTzZxbmUzd09zNnFIX1EzZkNWaXNnZ0NkWkE2UlRTV1ViYTZR?oc=5","date":"2025-05-05","type":"pipeline","source":"BioPharma Dive","summary":"Deerfield secures more than $600M for its next biotech venture fund - BioPharma Dive","headline":"Deerfield secures more than $600M for its next biotech venture fund","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxOZDhMX2NZdFM1UHltVjd5M2lsR0MwcE1rdkdISEtZWjZpcDR6MHU0bjRjVDExRnpIeXc1TkJ1T2RpcU1NanZ6azZZLVE4UkVNZFZzcnNjbURsenJzUndvSHVjZWpRczFfS19uNUctZ09sQm50M1ZoVVFfNnZHV0NPQjNLWVR1c2paZXRQOGFndWlkTkhxaXBDLTh4TnpFdWFrMTU3VDlwaHl3bVBTcHpicnVyZ1k4UUtQZHRCX2lMU21JZnV4d2JmYTdIVGM3SnV3YkJIbDU4cFFOVVFiWlFQRjRJeFJEa0VsSWhxYWI1czRwSDdPNFE?oc=5","date":"2024-06-17","type":"pipeline","source":"PR Newswire","summary":"Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund - PR Newswire","headline":"Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxONjI2THYyOU9rbVhMMDRXU1JWNF9zcjRaT0R2TXR3SU5iQTktN1FYTlY1YzQzSkstRVFGZGxsOWg1RThVWENZTkRmemYyMEhBZzZFWUJZZ2h1YVJzN1NKaVpBSmMzWEU0TXlUbVhaZ0JtLTZDZmxiM1JEU1dBcU1PMg?oc=5","date":"2024-01-04","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker '24: AusperBio adds $73M series B; Ottimo raises $140M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOS1UxWUpfOU1jdW0wWFU2ZTVGaUVvdUlReUkwcmpiNUJCNFE4dFhIbnVxWkRsSjdHb3N0WXpYZDFCbV9RU0t4c24wMmVnSkpoWVZLQ193OTViRnV2TVB0R3BFVkVwNmZZd0pxZ3VjS1pObm1Id0VnY3ZjNUwtN0NpOEpOZGJFdjVOVlAzZW1HZ3d0aTcwLXo1RHA5WGhfYS1QZFJOYUZsdmY1UDBSQnM0R0taOTBvcWZz?oc=5","date":"2021-01-27","type":"pipeline","source":"Dezeen","summary":"Demolition of Paul Rudolph's Burroughs Wellcome building underway in North Carolina - Dezeen","headline":"Demolition of Paul Rudolph's Burroughs Wellcome building underway in North Carolina","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}